Phytic Acid

Phytic Acid

SCHEMBL1172887

O=P(O)(O)O[C@H]1[C@H](OP(=O)(O)O)[C@@H](OP(=O)(O)O)[C@H](OP(=O)(O)O)[C@@H](OP(=O)(O)O)[C@H]1OP(=O)(O)O.O[Si](O)(O)O[SiH3]

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
ITPR3 Q14573 9/20 0.54
ITPR2 Q14571 5/20 0.52
ITPR1 Q14643 5/20 0.52
INPPL1 O15357 1/20 0.52
AKT1 P31749 1/20 0.52
SMPD1 P17405 1/20 0.50
INPP5A Q14642 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phytic Acid SCHEMBL141097 0.81 ITPR3 (0.77) ITPR3ITPR2ITPR1INPPL1AKT1
Phytic Acid SCHEMBL12138455 0.81 ITPR3 (0.77) ITPR3ITPR2ITPR1INPPL1AKT1
Phytic Acid SCHEMBL15374707 0.81 ITPR3 (0.77) ITPR3ITPR2ITPR1INPPL1AKT1
Phytic Acid SCHEMBL9164308 0.81 ITPR3 (0.77) ITPR3ITPR2ITPR1INPPL1AKT1
SCHEMBL8467566 0.81 ITPR3 (0.77) ITPR3ITPR2ITPR1INPPL1AKT1
Phytic Acid SCHEMBL1681701 0.81 ITPR3 (0.77) ITPR3ITPR2ITPR1INPPL1AKT1
Phytate SCHEMBL136587 0.81 ITPR3 (0.77) ITPR3ITPR2ITPR1INPPL1AKT1
Phytic Acid SCHEMBL17006482 0.81 ITPR3 (0.77) ITPR3ITPR2ITPR1INPPL1AKT1
Phytic Acid SCHEMBL9741350 0.81 ITPR3 (0.77) ITPR3ITPR2ITPR1INPPL1AKT1
Phytic Acid SCHEMBL9325946 0.81 ITPR3 (0.77) ITPR3ITPR2ITPR1INPPL1AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240237643-A1 COMPOSITIONS WITH VIRUCIDAL AND/OR ANTIVIRAL ACTIVITY SYMRISE AG (DE) 2024-07-18 US disclosed
US-20240216248-A1 MICROBIAL GLYCOLIPIDS ANALYTICON DISCOVERY GMBH (DE) 2024-07-04 US disclosed
EP-4387587-A1 COMPOSITIONS Symrise AG (DE) 2024-06-26 EP disclosed
WO-2024110023-A1 AN ACTIVE COMPOSITION COMPRISING RETINOL SYMRISE AG (DE) 2024-05-30 WO disclosed
WO-2024110515-A1 AN ACTIVE COMPOSITION COMPRISING RETINOL SYMRISE AG (DE) 2024-05-30 WO disclosed
US-20240173227-A1 A FRAGRANCE MIXTURE CONTAINING ISOCITRONELLOL SYMRISE AG (DE) 2024-05-30 US disclosed
WO-2024104625-A1 A BLEND OF EMOLLIENTS SYMRISE AG (DE) 2024-05-23 WO disclosed
WO-2024104546-A1 A BLEND OF EMOLLIENTS SYMRISE AG (DE) 2024-05-23 WO disclosed
US-20240122816-A1 ARTICLES FOR INDIRECT TRANSFER OF COSMETIC ACTIVES TO SKIN SYMRISE AG (DE) 2024-04-18 US disclosed
US-20240122834-A1 MEDICAMENT FOR PREVENTION AND TREATMENT OF HYPERPIGMENTATION SYMRISE AG (DE) 2024-04-18 US disclosed
WO-2006098980-A2 OIL GELS OF CONTROLLED DISTRIBUTION BLOCK COPOLYMERS AND ESTER OILS KRATON POLYMERS RESEARCH B.V. (NL) 2006-09-21 WO disclosed
US-20060205904-A1 Oil gels of controlled distribution block copolymers and ester oils UBS AG, STAMFORD BRANCH, AS COLLATERAL AGENT 2006-09-14 US disclosed
US-20060205849-A1 Oil gels of controlled distribution block copolymers and ester oils KRATON POLYMERS U.S. LLC 2006-09-14 US disclosed
EP-1141111-B1 GEL COMPOSITIONS PENRECO (US) 2005-08-03 EP disclosed
US-6881776-B2 Gel compositions PENRECO (US) 2005-04-19 US disclosed
US-20050004274-A1 Gel compositions HEALY LIN LU (US) 2005-01-06 US disclosed
EP-1256336-A2 Two-phase gel composition Penreco (US) 2002-11-13 EP disclosed
US-20020055562-A1 Gel compositions WILMINGTON TRUST, NATIONAL ASSOCIATION 2002-05-09 US disclosed
EP-1141111-A1 GEL COMPOSITIONS Penreco (US) 2001-10-10 EP disclosed
WO-2000026285-A1 GEL COMPOSITIONS PENRECO (US) 2000-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240122834-A1 MEDICAMENT FOR PREVENTION AND TREATMENT OF HYPERPIGMENTATION MC1R, OR51E2, TYR ITPR3 3657/4885ITPR2 4066/4885ITPR1 4202/4885
US-20240216248-A1 MICROBIAL GLYCOLIPIDS UGCG, SGMS1, GPR119 ITPR3 2717/4885ITPR2 2918/4885ITPR1 3003/4885
US-20240122816-A1 ARTICLES FOR INDIRECT TRANSFER OF COSMETIC ACTIVES TO SKIN CUTA, POLR1C, SLC16A7 ITPR3 4315/4885ITPR2 4628/4885ITPR1 4575/4885
US-20240237643-A1 COMPOSITIONS WITH VIRUCIDAL AND/OR ANTIVIRAL ACTIVITY ZC3HAV1, SAMHD1, ZC3HAV1L ITPR3 2735/4885ITPR2 3434/4885ITPR1 2813/4885
US-20240173227-A1 A FRAGRANCE MIXTURE CONTAINING ISOCITRONELLOL IPO5, OR51E2, FDFT1 ITPR3 783/4885ITPR2 1254/4885ITPR1 987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.